Trial Profile
A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib GS-1101 in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary) ; Ofatumumab
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 21 Jun 2020 Results (N=408), pooled analysis of 4 studies assessing efficacy of Idelalisib in patients with indolent non Hodgkins lymphoma and CLL, presented at the 25th Congress of the European Haematology Association
- 05 Aug 2019 Status changed from completed to discontinued.
- 04 Dec 2018 Results using a comprehensive approach to derive and validate a novel risk model for OS in 2,475 patients with R/R CLL who received therapy in randomized phase 3 trials (NCT01611090, NCT01578707, NCT01569295, NCT01539512, NCT01659021 and NCT02005471) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology